Health Care Resource Utilization: Luspatercept vs ESAs in MDS

Saeed Sadeghi, MD, discusses the impact of health care resource utilization on treatment decisions and quality of life for patients with myelodysplastic syndromes (MDS), highlighting real-world data presented at SOHO that compares the resource utilization of U.S. patients treated with luspatercept versus erythropoiesis-stimulating agents (ESAs).

EP: 1.Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS

EP: 2.COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment

EP: 3.Real-World Data on Luspatercept in LR-MDS

Now Viewing

EP: 4.Health Care Resource Utilization: Luspatercept vs ESAs in MDS

EP: 5.Current Approach to Treating Anemia in LR-MDS

EP: 6.Future Perspective on Anemia Treatment in LR-MDS

Video content above is prompted by the following:

Health care resource utilization is an important factor in deciding on treatments and affects quality of life for patients.

• Please briefly discuss the real-world data presented at SOHO comparing the health resource utilization of US patients with MDS treated with luspatercept vs ESAs.

Recent Videos